ONO Pharmaceutical Completes Two Key Oncology Studies as Pipeline Advances
Key Insights
ONO Pharmaceutical (search) has completed a real-world evidence study of tirabrutinib in Taiwan for patients with relapsed or refractory primary central nervous system lymphoma (search), with findings potentially supporting broader market access.
The company also finished a phase I combination trial testing ONO-7475 with AstraZeneca's Tagrisso in advanced EGFR (search)-mutated non-small cell lung cancer (search) patients.
Both completed studies represent strategic opportunities for ONO to strengthen its oncology portfolio, with real-world data potentially aiding reimbursement discussions and the lung cancer combination offering potential for larger trials.
ONO Pharmaceutical (search) Co., Ltd. has reached completion milestones for two significant oncology studies, positioning the company for potential data readouts that could influence its competitive standing in specialized cancer markets.
Real-World Evidence Study in CNS Lymphoma
The Japanese pharmaceutical company completed a nationwide observational study in Taiwan evaluating tirabrutinib's real-world effectiveness and safety in patients with relapsed or refractory primary central nervous system lymphoma (search). The study, titled "Real-World Evidence of Effectiveness and Safety of Tirabrutinib in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma in Taiwan," was designed to capture how the drug performs outside controlled clinical trial settings.
Tirabrutinib is a targeted oral medicine designed to block a key pathway that helps certain blood cancers grow. The observational cohort study followed patients already receiving tirabrutinib treatment, allowing researchers to document everyday use patterns and outcomes in normal clinical practice. This approach complements earlier controlled clinical trials by providing insights into real-world treatment effectiveness.
The study was first submitted to registries on November 5, 2024, and reached completed status with the most recent update filed on May 18, 2026. The completion indicates that the dataset is locked and findings are likely being analyzed or prepared for disclosure.
Lung Cancer Combination Trial
ONO also completed its phase I study ONO-7475-03, which tested the combination of ONO-7475 with AstraZeneca's Tagrisso (osimertinib) in patients with advanced EGFR (search)-mutated non-small cell lung cancer (search). The trial aimed to evaluate the safety and tolerability of this combination as a first-line treatment option for patients who cannot receive intensive radiation therapy.
The study used once-daily dosing of both ONO-7475 and osimertinib mesylate. ONO-7475 is an oral small-molecule drug being explored to enhance the effectiveness of standard EGFR (search) therapy, while osimertinib is already established as the leading targeted treatment for EGFR-positive lung cancer.
This open-label, non-randomized interventional trial focused primarily on treatment safety and optimal dosing rather than comparative effectiveness. The study was first registered on July 24, 2024, with the latest update filed on March 11, 2026, indicating recent sponsor activity and suggesting potential near-term data disclosure.
Strategic Implications
For the tirabrutinib study, strong real-world effectiveness and safety data could support broader use of the drug and aid in reimbursement negotiations, potentially strengthening ONO's position in niche lymphoma markets compared to other BTK (search) inhibitors and oncology competitors.
The lung cancer combination study represents a strategic opportunity rather than immediate revenue potential. A positive safety profile could justify larger combination trials with Tagrisso in the high-value EGFR (search)-mutated lung cancer segment. Success in demonstrating that ONO-7475 enhances efficacy without introducing significant new risks would support ONO's research and development narrative and potentially influence investor assessment of its competitive position.
However, ONO faces challenges in both therapeutic areas. In the BTK (search) inhibitor space, competition remains intense, while AstraZeneca's established position with Tagrisso and the presence of competing EGFR (search) and resistance-pathway assets worldwide create a crowded competitive landscape for lung cancer treatments.
Both studies have reached completion status, with analysis underway and potential data readouts expected in upcoming reporting cycles.